MERIT Acquires OSOD to Expand Ophthalmic Drug Development Services

MERIT announced its has acquired OSOD, which assists with ophthalmic preclinical drug development. The acquisition enhances MERIT’s capabilities, enabling a transition from preclinical to clinical phases of drug development.

According to MERIT, OSOD has played a pivotal role in advancing numerous ophthalmic therapies, including Lucentis, Eylea, Xiidra, Susvimo, and Durysta, from preclinical research to market approval. 

“OSOD has always been committed to excellence in early-stage ophthalmology research. Joining forces with MERIT allows us to extend our impact and contribute to the entire drug development continuum," Christopher Murphy, CEO of OSOD, said in a company news release. "Importantly, the entire management team, employees, and our distributed network of experts in vision science and drug development remain committed to advancing the impact of OSOD in ocular drug development. We look forward to leveraging the resources and capabilities of MERIT to the benefit of our clients in bringing much-needed therapeutics to the marketplace to benefit patients.”